Literature DB >> 1804810

Phase II study of lonidamine in metastatic prostatic carcinoma.

D J Stewart1, S E Aitken, A H Irvine, D E Moors, N G Futter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1804810     DOI： 10.1007/BF00183577

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  5 in total

Review 1.  A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.

Authors:  M A Eisenberger; R Simon; P J O'Dwyer; R E Wittes; M A Friedman
Journal:  J Clin Oncol       Date:  1985-06       Impact factor: 44.544

2.  Radiosensitization of Meth-A fibrosarcoma in mice by Lonidamine.

Authors:  J H Kim; A Alfieri; S H Kim; C W Young; B Silvestrini
Journal:  Oncology       Date:  1984       Impact factor: 2.935

3.  Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

Authors:  I F Tannock
Journal:  J Clin Oncol       Date:  1985-07       Impact factor: 44.544

4.  Phase II evaluation of Lonidamine in patients with advanced malignancy.

Authors:  W K Evans; F A Shepherd; B Mullis
Journal:  Oncology       Date:  1984       Impact factor: 2.935

5.  In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin.

Authors:  G Zupi; C Greco; N Laudonio; M Benassi; B Silvestrini; A Caputo
Journal:  Anticancer Res       Date:  1986 Sep-Oct       Impact factor: 2.480
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.